Neuronet is a Coordination and Support Action (CSA) aiming to support and better integrate projects in the Innovative Medicines Initiative (IMI) Neurodegenerative Disorders (ND) portfolio. Currently, the IMI ND portfolio includes 17 projects covering a number of neurodegenerative disease conditions. We are happy to welcome the Mobilise-D project in the Neuronet programme.
Mobilise-D is funded through the Innovative Medicines Initiative (IMI). It is a five year project (2019-2024) that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy. The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care. More than 150 professionals from 34 participating universities, hospitals, and industry with the necessary technical, clinical, and regulatory expertise are working together to reach the common goal of validating health care technology.
Lynn Rochester (Newcastle University) is Mobilise-D representative on Neuronet’s Scientific Coordination Board.
For more information on the Mobilise-D project:
Twitter handle: @Mobilise_D